June 17, 2020
Today, iCubate board chairman Jian Han announced a change in leadership of the company. Carter Wells, chief executive officer since 2010, will move into a consulting role and veteran biotech executive Dennis Grimaud will join the company as chief executive.
“I would like to thank the outstanding team at iCubate for their dedicated work and achievements over the years. It has been an honor to lead this team and work collaboratively to achieve FDA clearances, international agreements and most of all, the COVID19 assay which puts us fully in the fight against the pandemic. I am grateful for the support and guidance of the board of directors and shareholders,” said Mr. Wells.
“This is the right time for a change and I look forward to focusing my efforts on the growth of HudsonAlpha (Institute for Biotechnology)”, continued Mr. Wells. “I am eager to continue working with biotech entrepreneurs as they move discoveries into applications benefiting people everywhere.”
iCubate founder, chairman and chief scientific officer, Jian Han, added, “We appreciate Carter’s leadership as the company met milestones involving technology development, manufacturing, regulatory clearances and market integration. The most important achievement during his time as CEO is that iCubate assays are now in the field improving patient care. Carter has built a team that will continue to serve the company well. We welcome Dennis back to the iCubate team and anticipate great days ahead.”
Bringing decades of experience in the healthcare industry and as an entrepreneur, senior executive and consultant, Mr. Grimaud returns to iCubate, where he was a founding board member until 2013.
Mr. Grimaud was chairman, chief executive officer and founder of DIATHERIX Laboratories, a clinical laboratory that provides testing services to physicians and hospitals for the identification of infectious disease. Additionally, he served as CEO of Genaco Biomedical Products, also founded by Dr. Han. Genaco was acquired by Qiagen in 2006.
Under Mr. Wells’s leadership, iCubate has achieved FDA clearances and CE marks on comprehensive bloodstream infection diagnostic tests; entered into successful international licensing and joint venture agreements; made its initial integration into the U.S. market; received a “breakthrough device” designation by the FDA; and developed a diagnostic test for COVID19. Mr. Wells will continue working for the biotech industry through his role as HudsonAlpha’s Vice President for Economic Development. Dr. Han and Mr. Grimaud will now work together for further commercial success and to meet the future goals of the company.